166 related articles for article (PubMed ID: 3873988)
21. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Guo QL; Wu MS; Chen Z
Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
Testorelli C; Archetti YL; Aresca P; Del Vecchio L
Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
[TBL] [Abstract][Full Text] [Related]
23. Effects of levamisole administration on treatment with 6-mercaptopurine riboside of mice bearing L1210 leukemia cells.
Miura T; Nogiwa E; Kurashige S; Maekawa T
Cancer Res; 1980 Dec; 40(12):4813-6. PubMed ID: 7438114
[TBL] [Abstract][Full Text] [Related]
24. Blastogenic potency of concanavalin-A-bound L1210 leukemic vaccine associated with its immunogenic activity.
Kataoka T; Oh-hashi F; Sakurai Y
Gan; 1979 Apr; 70(2):155-64. PubMed ID: 111995
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
Fuji H
Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
[TBL] [Abstract][Full Text] [Related]
26. Environmental conditions favorable for tumor progression in peritoneal cavity induced by peritoneal cells without tumor selectivity.
Segawa K; Ueno Y; Kataoka T
Jpn J Exp Med; 1989 Jun; 59(3):127-33. PubMed ID: 2681889
[TBL] [Abstract][Full Text] [Related]
27. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
[TBL] [Abstract][Full Text] [Related]
29. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study.
Seledtsov VI; Taraban VY; Seledtsova GV; Samarin DM; Avdeev IV; Senyukov VV; Kozlov VA
Cell Immunol; 1997 Nov; 182(1):12-9. PubMed ID: 9427805
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of a unique tumor-associated surface antigen on L1210 leukemia cells recognized by semisyngeneic antisera.
Yokochi T; Kawashima K; Nakashima I; Nagase F; Isobe K; Nagura E; Yamada K; Miyadai T; Kimura Y
Cancer Res; 1987 Feb; 47(4):1006-9. PubMed ID: 3542198
[TBL] [Abstract][Full Text] [Related]
31. [Modulation of the antitumor activity of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a by O(6)-methyl-2'-deoxyguanosine--a new inhibitor of O(6)-alkylguanine-DNA-alkyltransferase].
Dederer LIu; Sokolova IS; Bakhmedova AA; Miniker TD; Mel'nik SIa; Gorbacheva LB
Biokhimiia; 1995 Sep; 60(9):1521-9. PubMed ID: 8562657
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity.
Lee FH; Currie D; Hwang KM
Cancer Res; 1984 Dec; 44(12 Pt 1):5491-8. PubMed ID: 6208997
[TBL] [Abstract][Full Text] [Related]
33. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor.
Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
Cancer Res; 1977 Dec; 37(12):4416-9. PubMed ID: 922733
[TBL] [Abstract][Full Text] [Related]
34. Cellular mechanism of primary anti-Thy-1 antibody responses in vitro induced by uniquely immunogenic thymocyte antigens.
Isobe KI; Nakashima I; Nagase F; Kato N; Mizoguchi K; Kawashima K; Lake P
J Immunol; 1984 Mar; 132(3):1100-5. PubMed ID: 6141204
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
36. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
37. [Elimination of suppressor macrophages in tumor-bearing mice by 6-mercaptopurine and its therapeutic contribution].
Kataoka T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):701-5. PubMed ID: 3963841
[TBL] [Abstract][Full Text] [Related]
38. [Production by activated lymphocytes of mediators increasing the antitumor cytostatic activity of bone marrow cells].
Seledtsov VI; Taraban VIa; Seledtsova GV; Seniukov VV; Samarin DM; Kashchenko EA; Kozlov VA
Biull Eksp Biol Med; 1998 Jun; 125(6):660-2. PubMed ID: 9693761
[No Abstract] [Full Text] [Related]
39. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
[TBL] [Abstract][Full Text] [Related]
40. Establishment of a murine leukemia L1210-specific T-cell clone displaying novel in vivo anti-tumor activity.
Nagase F; Ueda K; Nakashima I; Kawashima K; Isobe K; Nagura E; Yamada K; Yokochi T; Hasegawa Y; Yoshida T
Int J Cancer; 1986 Dec; 38(6):907-14. PubMed ID: 3491792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
